| Literature DB >> 31912874 |
Lijuan Sun1, Jianhua Yan2,3,4, Hui Jen Goh1, Priya Govindharajulu1, Sanjay Verma5, Navin Michael6, Suresh Anand Sadananthan6, Christiani Jeyakumar Henry1,7, S Sendhil Velan5,6,8, Melvin Khee-Shing Leow1,9,10,11.
Abstract
BACKGROUND: Adipocyte-derived hormones play a role in insulin sensitivity and energy homeostasis. However, the relationship between circulating fibroblast growth factor 21 (FGF21), adipocytokines and cold-induced supraclavicular brown adipose tissue (sBAT) activation is underexplored.Entities:
Keywords: FGF21; TNFα; adiponectin; cold-induced supraclavicular BAT activity; leptin
Year: 2020 PMID: 31912874 PMCID: PMC7015460 DOI: 10.1210/clinem/dgaa005
Source DB: PubMed Journal: J Clin Endocrinol Metab ISSN: 0021-972X Impact factor: 5.958
Characteristics of Total Participants and Participants With and Without BAT After Cold Exposure
| Total (19) | BAT-positive (12) | BAT-negative (7) |
| |
|---|---|---|---|---|
| Age (years) | 26.0 ± 1.0 | 26.9 ± 1.2 | 24.4 ± 1.4 | 0.22 |
| BMI (kg/m2) | 21.7 ± 0.6 | 21.7 ± 0.8 | 21.8 ± 0.9 | 0.95 |
| Body weight (kg) | 62.1 ± 3.0 | 63.8 ± 4.1 | 59.2 ± 4.0 | 0.46 |
| Body fat (%) | 29.7 ± 1.8 | 29.4 ± 2.8 | 30.1 ± 1.5 | 0.85 |
| Fat mass (kg) | 18.6 ± 1.8 | 19.2 ± 2.7 | 17.6 ± 1.0 | 0.67 |
| SAT (cm3) | 1868 ± 223 | 1740 ± 364 | 2234 ± 221 | 0.53 |
| VAT (cm3) | 491 ± 88 | 499 ± 98 | 480 ± 168 | 0.92 |
| SSAT (cm3) | 1059 ± 96 | 1000 ± 142 | 1136 ± 127 | 0.50 |
| DSAT (cm3) | 809 ± 133 | 740 ± 225 | 898 ± 107 | 0.57 |
| RMR (kcal/day) | 1569 ± 75 | 1574 ± 88 | 1561 ± 145 | 0.94 |
| Glucose (mmol/L) | 5.5 ± 0.1 | 5.5 ± 0.2 | 5.4 ± 0.07 | 0.78 |
| Insulin (µIU/mL) | 10.0 ± 1.0 | 10.0 ± 1.4 | 10.0 ± 1.1 | 1.00 |
| HOMA-IR score | 2.45 ± 0.25 | 2.48 ± 0.38 | 2.40 ± 0.27 | 0.89 |
| Triglyceride (mmol/L) | 0.9 ± 0.06 | 1.0 ± 0.1 | 0.7 ± 0.1 | 0.04 |
| NEFA (mmol/L) | 0.7 ± 0.03 | 0.7 ± 0.04 | 0.7 ± 0.04 | 0.26 |
| FGF21(pg/mL) | 85.7 ± 20.2 | 88.4 ± 28.5 | 81.1 ± 27.9 | 0.87 |
| Leptin (pg/mL) | 5041 ± 1103 | 5555 ± 1686 | 4159 ± 878 | 0.56 |
| Adiponectin (ng/mL) | 8703 ± 688 | 8321 ± 673 | 9359 ± 1524 | 0.48 |
| TNFα (pg/mL) | 3.0 ± 0.2 | 3.0 ± 0.2 | 2.9 ± 0.3 | 0.89 |
Data presented as mean ± SEM. P values represents Student t-test between BAT-positive and BAT-negative participants.
Abbreviations: BAT, brown adipose tissue; BMI, body mass index (calculated as body weight [kg] divided by the square of height [m]); DSAT, deep subcutaneous adipose tissue; FGF21, fibroblast growth factor-21, HDL, high-density lipoprotein; HOMA-IR, homeostasis model assessment of insulin resistance (calculated as fasting glucose × fasting insulin divided by 22.5); NEFA, non-esterified fatty acids; RMR, resting metabolic rate; SAT, subcutaneous adipose tissue; SSAT, superficial subcutaneous adipose tissue; TNFα, tumor necrosis factor-alpha; VAT, visceral adipose tissue.
Correlations Between FGF21, Leptin, Adiponectin, TNFα, and Body Composition Blood Markers at Baseline in Total Participants
| FGF21 | Leptin | Adiponectin | TNFα | |||||
|---|---|---|---|---|---|---|---|---|
| Measure | Coefficient ( |
| Coefficient ( |
| Coefficient ( |
| Coefficient ( |
|
| BMI (kg/m2) | 0.49 | 0.09 |
|
| 0.02 | 0.95 | -0.27 | 0.33 |
| fat mass (kg) | 0.41 | 0.17 |
|
| -0.13 | 0.67 | -0.42 | 0.12 |
| % fat mass | 0.38 | 0.21 |
|
| -0.37 | 0.22 |
|
|
| SAT (cm3) | 0.43 | 0.14 |
|
| -0.18 | 0.55 | -0.46 | 0.09 |
| VAT (cm3) | 0.25 | 0.40 | 0.54 | 0.06 | -0.18 | 0.56 | -0.08 | 0.79 |
| SSAT (cm3) | 0.43 | 0.14 |
|
| -0.16 | 0.60 | -0.35 | 0.20 |
| DSAT (cm3) | 0.42 | 0.16 |
|
| -0.19 | 0.53 |
|
|
| REE (kcal/day) | 0.15 | 0.63 |
|
| -0.15 | 0.62 | -0.25 | 0.37 |
| Glucose (mmol/L) | -0.15 | 0.63 | 0.04 | 0.90 | 0.12 | 0.71 | -0.01 | 0.99 |
| Insulin (µIU/L) | 0.05 | 0.88 | 0.29 | 0.34 | -0.22 | 0.48 | -0.27 | 0.34 |
| HDL (mmol/L) | -0.31 | 0.31 |
|
|
|
| 0.38 | 0.17 |
| Triglyceride (mmol/L) | -0.25 | 0.41 | 0.13 | 0.66 | -0.45 | 0.12 | 0.16 | 0.56 |
| NEFA (mmol/L) | -0.27 | 0.38 | 0.05 | 0.88 | 0.50 | 0.08 | 0.34 | 0.22 |
N = 19, Correlations were used to assess relationship between variables after adjusting for sex. Significant correlations between variables are shown in bold with corresponding coefficient (r) and P values adjusted for sex.
Abbreviations: BMI, body mass index (calculated as body weight [kg] divided by the square of height [m]); DSAT, deep subcutaneous adipose tissue; FGF21, fibroblast growth factor-21, HDL, high-density lipoprotein; NEFA, non-esterified fatty acids; REE, resting energy expenditure; SAT, subcutaneous adipose tissue; SSAT, superficial subcutaneous adipose tissue; TNFα, tumor necrosis factor-alpha; VAT, visceral adipose tissue.
FGF21, Leptin, Adiponectin and TNFa Concentrations at Baseline and Post Intervention at 2 Hours After Cold Exposure in All, BAT-Positive, and BAT-Negative Participants
| Total Participants (n = 19) | BAT-Positive Participants (n = 12) | BAT-Negative Participants (n = 7) | Treatment Effects | BAT-Status Effects | Interaction | ||||
|---|---|---|---|---|---|---|---|---|---|
| Baseline | 120 min | Baseline | 120 min | Baseline | 120 min |
| |||
| FGF21 (pg/mL) | 85.7 ± 20.2 | 58.4 ± 11.9 | 88.4 ± 28.5 | 51.6 ± 12.9 | 81.1 ± 27.9 | 69.9 ± 24.3 | 0.45 | 0.61 | 0.04 |
| Leptin (pg/mL) | 5041 ± 1103 | 3102 ± 767* | 5555 ± 1686 | 3549 ± 1181 | 4159 ± 878 | 2335 ± 496 | 0.001 | 0.99 | 0.30 |
| Adiponectin (ng/mL) | 8703 ± 688 | 7867 ± 657* | 8321 ± 673 | 7314 ± 635 | 9359 ± 1524 | 8815 ± 1419 | 0.002 | 0.37 | 0.28 |
| TNFα (pg/mL) | 3.0 ± 0.2 | 2.9 ± 0.2 | 3.0 ± 0.2 | 3.0 ± 0.3 | 2.9 ± 0.3 | 2.7 ± 0.5 | 0.12 | 0.65 | 0.15 |
Data presented as mean ± SEM. The treatment effects, BAT-status effects, and interactions between treatment and BAT status were tested using linear mixed effects model.
Abbreviations: BAT, brown adipose tissue; FGF21, fibroblast growth factor-21; TNFα, tumor necrosis factor-α.
# P < 0.05 compared with baseline in each group participants; *<0.01 compared with baseline in each group participants.
Summary of Outcomes of Adipokines After Cold Exposure in 12 BAT-Positive Participants
| Female Participants (n = 6) | Male Participants (n = 6) | Treatment Effects | Gender Effects | Treatment × Gender Interaction | |||
|---|---|---|---|---|---|---|---|
| Baseline | 120 min | Baseline | 120 min |
| |||
| FGF21(pg/mL) | 122.0 ± 55.2 | 63.2 ± 24.7 | 54.9 ± 8.7 | 40.1 ± 8.4 | 0.04 | 0.29 | 0.20 |
| Leptin (pg/mL) | 7937 ± 2998 | 4926 ± 2176 | 3173 ± 1122 | 2172 ± 803 | 0.001 | 0.20 | 0.05 |
| Adiponectin (ng/ mL) | 8770 ± 1329 | 7299 ± 1231 | 7871 ± 378 | 7329 ± 509 | <0.001 | 0.75 | 0.03 |
| TNFα (pg/mL) | 2.7 ± 0.4 | 2.6 ± 0.3 | 3.3 ± 0.2 | 3.4 ± 0.3 | 0.92 | 0.16 | 0.30 |
N = 12; Values are mean ± SEM; The treatment effects, gender effects and interactions between treatment and gender were tested using linear mixed effects model while controlling for the baseline measurements.
Abbreviations: BAT, brown adipose tissue; FGF21, fibroblast growth factor-21; TNFα, tumor necrosis factor-α.
Regression Results of Adipocytokines Markers With Imaging Parameters and EE After Cold Exposure in BAT-Positive Participants
| sBAT PET SUV Mean | MR sFF | IRT Tscv max | EE % change | |||||
|---|---|---|---|---|---|---|---|---|
| Measure | Coefficient (β) ± SEM |
| Coefficient (β) ± SEM |
| Coefficient (β) ± SEM |
| Coefficient (β) ± SEM |
|
|
| ||||||||
| FGF21 (pg/mL) | −1.4 ± 40.4 | 0.97 | 0.76 ± 4.82 | 0.88 | −4.4 ± 90.6 | 0.96 | −2.0 ± 5.0 | 0.70 |
| Leptin (pg/mL) | 720 ± 1632 | 0.67 | −63.2 ± 196.6 | 0.76 | 3628 ± 3452 | 0.33 | −27.8 ± 206.0 | 0.90 |
| Adiponectin (ng/ mL) |
|
|
|
|
|
| 285 ± 164 | 0.13 |
| TNFα (pg/mL) | 0.70 ± 0.41 | 0.13 | −0.06 ± 0.05 | 0.27 | 1.50 ± 0.93 | 0.15 | 0.07 ± 0.06 | 0.27 |
|
| ||||||||
| FGF21(pg/mL) | 10.9 ± 8.4 | 0.24 |
|
| 7.6 ± 21.2 | 0.73 | 0.86 ± 1.2 | 0.48 |
| Leptin (pg/mL) | 271 ± 164 | 0.15 | −32.4 ± 19.4 | 0.15 | −262 ± 459 | 0.59 | −2.1 ± 24.3 | 0.93 |
| Adiponectin (ng/ mL) |
|
| 1.3 ± 67.5 | 0.99 | −197 ± 1081 | 0.86 | 75.9 ± 38.5 | 0.10 |
| TNFα (pg/mL) |
|
| 0.03 ± 0.03 | 0.37 | −0.59 ± 0.56 | 0.34 | 0.01 ± 0.03 | 0.68 |
| Change from baseline | ||||||||
| ∆ FGF21(pg/mL) | 11.7 ± 24.0 | 0.64 | −2.5 ± 2.8 | 0.40 | 10.1 ± 54.6 | 0.86 | 1.97 ± 2.95 | 0.53 |
| ∆ Leptin (pg/mL) | 56.7 ± 508 | 0.91 | −13.8 ± 60.6 | 0.83 | −1268 ± 1035 | 0.26 | 5.8 ± 63.3 | 0.93 |
| ∆ Adiponectin (ng/mL) |
|
| 26.5 ± 37.4 | 0.50 | −532 ± 698 | 0.47 | 34.7 ± 38.1 | 0.39 |
| ∆ TNFα (pg/mL) |
|
| 0.04 ± 0.03 | 0.20 | −0.70 ± 0.45 | 0.16 | 0.01 ± 0.03 | 0.98 |
N = 12. SUV calculated from PET integrated in 80 minutes after cold exposure; FF from MR at the start of the scan after cold exposure; Tscv max from peak of IRT analysis within 120 minutes in the supraclavicular region and EE percentage change from baseline in 120 minutes after cold exposure. The baseline and change from baseline analysis were adjusted with gender, body fat percentage, and HOMA-IR. The 120-min cold exposure analysis was adjusted with baseline value, gender, body fat percentage, and HOMA-IR. Significant regression between variables are shown in bold with corresponding Standardized Coefficient (β) ± SEM and P values.
Abbreviations: BAT, brown adipose tissue; EE, energy expenditure; FGF21, fibroblast growth factor 21; HOMA-IR, homeostatic model assessment for insulin resistance; IRT, infrared thermography; MR, magnetic resonance; PET, positron-emission tomography; sBAT, supraclavicular brown adipose tissue; SEM, standard error of the mean; sFF, supraclavicular fat fraction; SUV, standardized uptake value; TNF, tumor necrosis factor; Tscv max, supraclavicular maximum temperature.
Figure 1.Spearman correlations of plasma FGF21 concentration percentage change (%) and adiponectin concentration at baseline (A, D), 120 minutes after cold exposure (B, E) and percentage change from baseline (C, F) after adjustment for sex in BAT-positive subjects (A, B, C) and BAT-negative subjects (D, E, F). Abbreviation: FGF21, fibroblast growth factor 21.